Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

NCT01142661 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Eribulin Mesylate

Sponsor

Eisai Inc.